Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of triple class refractory multiple myeloma

Karun Neupane, Ahsan Wahab, Adeel Masood, Tehniat Faraz, Saman Bahram, Hamid Ehsan, Abdul Hannan, Faiz Anwer

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Treatment options are limited for multiple myeloma patients who have developed four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs is a concern since these agents are used in patients who have already undergone multiple lines of treatment. In this review, we discuss the toxicity profile and strategies for the management of toxicities of Sel and belamaf for the treatment of RRMM. We conducted a comprehensive literature search on PubMed, Embase, Cochrane, and Clinicaltrials.gov using the terms “selinexor”, “belantamab”, “belamaf”, and “multiple myeloma” without applying any limitations based on the date of the study, language, or country of origin. The most common hematological toxicity associated with these two drugs is thrombocyto-penia. Cytopenias, constitutional symptoms, gastrointestinal effects, and hyponatremia are the major toxicities of Sel. Keratopathy and anemia are the major toxicities of belamaf. Treatment modifications and dose interruption are usually needed when side effects are more than grade II. As these are newer drugs with limited data, continuous surveillance and monitoring are warranted during the treatment course with early mitigation strategies.

Original languageEnglish (US)
Pages (from-to)529-550
Number of pages22
JournalJournal of Blood Medicine
Volume12
DOIs
StatePublished - 2021
Externally publishedYes

Keywords

  • Hematological malignancy
  • Ocular toxicity
  • Relapsed and refractory multiple myeloma
  • Safety
  • Treatment

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Profile and management of toxicity of selinexor and belantamab mafodotin for the treatment of triple class refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this